Literature DB >> 22182247

Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.

Guanglong Dong1, Xu Guo, Xiaoying Fu, Shaogui Wan, Feng Zhou, Ronald E Myers, Guoqiang Bao, Ashlie Burkart, Hushan Yang, Jinliang Xing.   

Abstract

Angiogenesis plays a key role in the development and treatment response of various tumors. The signaling transductions mediated by the binding of vascular endothelial growth factor (VEGF) to its receptor KDR (kinase insert domain receptor) is the most important pathway in tumor angiogenesis. Single nucleotide polymorphisms (SNPs) in VEGF have been extensively implicated in the etiology and treatment outcome of colorectal cancer (CRC). However, no study has been reported evaluating the role of KDR SNPs in CRC prognosis. We herein assessed the association between four potentially functional KDR SNPs and tumor recurrence in a Chinese population with 408 surgically resected CRC patients. The most significant SNP was for rs10013228 located in the KDR gene promoter. Compared with the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with a reduced recurrence risk with a hazard ratio (HR) of 0.53 (95% confidence interval [CI] 0.30-0.95, P = 0.032). Moreover, a borderline significant association was noted for another promoter SNP, rs2071559, with an HR of 0.67 (95% CI 0.42-1.07, P = 0.092). In stratified analysis, the associations of both SNPs were more prominent in patients receiving chemotherapy (HR = 0.47, 95% CI 0.23-0.94, P = 0.033 for rs10013228 and HR = 0.55, 95% CI 0.32-0.95, P = 0.032 for rs2071559). Further analysis revealed a protective effect on patient recurrence by chemotherapy (HR = 0.56, 95% CI 0.32-1.01, P = 0.046), which was more evident in patients with the variant-containing genotypes of each of the two SNPs (HR = 0.09, 95% CI 0.02-0.55, P = 0.009 for rs10013228 and HR = 0.39, 95% CI 0.18-0.86, P = 0.020 for rs2071559). Collectively, our findings suggest SNPs in the KDR gene modulate CRC recurrence, especially in those receiving chemotherapy.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22182247     DOI: 10.1111/j.1349-7006.2011.02194.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  19 in total

1.  Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.

Authors:  Ellen Heitzer; Sandra Sunitsch; Magdalena M Gilg; Birgit Lohberger; Beate Rinner; Karl Kashofer; Nicole Stündl; Peter Ulz; Joanna Szkandera; Andreas Leithner; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.

Authors:  I Sullivan; J Salazar; C Arqueros; M Andrés; A Sebio; M Majem; J Szafranska; E Martínez; D Páez; A López-Pousa; M Baiget; A Barnadas
Journal:  Clin Transl Oncol       Date:  2017-02-01       Impact factor: 3.405

Review 3.  Genetic variations in colorectal cancer risk and clinical outcome.

Authors:  Kejin Zhang; Jesse Civan; Sushmita Mukherjee; Fenil Patel; Hushan Yang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.

Authors:  Mayank Jauhri; Akanksha Bhatnagar; Satish Gupta; Yogender Shokeen; Sachin Minhas; Shyam Aggarwal
Journal:  Med Oncol       Date:  2016-08-27       Impact factor: 3.064

5.  Correlation between VEGFR2 rs2071559 polymorphism and glioma risk among Chinese population.

Authors:  Guo-Zheng Xu; Ying Liu; Yi Zhang; Jing Yu; Bo Diao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.

Authors:  L Paré-Brunet; A Sebio; J Salazar; A Berenguer-Llergo; E Río; A Barnadas; M Baiget; D Páez
Journal:  Pharmacogenomics J       Date:  2015-02-24       Impact factor: 3.550

7.  Genetic Variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) Are Associated with Glioma Risk in a Han Chinese Population: a Case-Control Study.

Authors:  Jiannan Zhang; Jian Yang; Yuqing Chen; Qin Mao; Shanquan Li; Wenhao Xiong; Yingying Lin; Jie Chen; Jianwei Ge
Journal:  Mol Neurobiol       Date:  2015-06-21       Impact factor: 5.590

8.  Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.

Authors:  Ines P Silva; Amel Salhi; Keith M Giles; Matjaz Vogelsang; Sung W Han; Naima Ismaili; Kevin P Lui; Eric M Robinson; Melissa A Wilson; Richard L Shapiro; Anna Pavlick; Judy Zhong; Tomas Kirchhoff; Iman Osman
Journal:  Clin Cancer Res       Date:  2015-12-02       Impact factor: 12.531

9.  Dysregulated KDR and FLT1 Gene Expression in Colorectal Cancer Patients.

Authors:  Fatemeh Mohammad Rezaei; Shahryar Hashemzadeh; Reyhaneh Ravanbakhsh Gavgani; Mohammadali Hosseinpour Feizi; Nasser Pouladi; Hossein Samadi Kafil; Leila Rostamizadeh; Vahid Kholghi Oskooei; Mohammad Taheri; Ebrahim Sakhinia
Journal:  Rep Biochem Mol Biol       Date:  2019-10

10.  The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab.

Authors:  Shu-Dong Zhang; Cian M McCrudden; Chen Meng; Yao Lin; Hang Fai Kwok
Journal:  Onco Targets Ther       Date:  2015-04-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.